Douglas Flora, MD, LSSBB, discusses how the use of artificial intelligence tools could improve patient screening and drug development in oncology.
Douglas B. Flora, MD, LSSBB
Advertisement
Douglas B. Flora, MD, LSSBB, is the executive medical director of Oncology Services and the Robert and Dell Ann Sathe Endowed Chair in Oncology at St. Elizabeth Healthcare.
Articles by Douglas B. Flora, MD, LSSBB
Douglas B. Flora, MD, LSSBB, discusses the potential utility of GPT models for improving clinical trial screening and workflows in oncology.
Douglas B. Flora, MD, LSSBB, discusses the rationale for assessing BXQ-350 plus mFOLFOX7 and bevacizumab in a phase 1/2 trial of patients with mCRC.
Advertisement
Latest Updated Articles
Dr Flora on the Mechanism of Action of BXQ-350 in Newly Diagnosed CRCFebruary 26th 2025
Advertisement
Advertisement
Trending on OncLive
1
TP53 Status and Time Toxicity Shape Sequencing Decisions in EGFR-Mutated NSCLC
2
Divarasib Outperforms First-Generation KRAS G12C Inhibitors in Phase 3 NSCLC Trial
3
Savolitinib Gains NMPA Approval for MET-Amplified Gastric and GEJ Adenocarcinoma
4
Rusfertide Maintains Long-Term Thromboembolism Control in Phlebotomy-Dependent Polycythemia Vera
5